Association of CYP2C19 Loss-of-Function Alleles with Major Adverse Cardiovascular Events of Clopidogrel in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: Meta-analysis

[1] Braun MM(2018)Stable coronary artery disease:treatment Am Fam Physician 97 376-384

[2] Stevens WABC(2015)CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: a systematic review and meta-analysis J Huazhong Univ Sci Technol - Med Sci 35 147-156

[3] Niu X(2000)Identification and biological activity of the active metabolite of clopidogrel Thromb Haemost 84 891-896

[4] Mao L(2013)Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease JACC Cardiovasc Interv 6 1166-1175

[5] Huang Y(2011)Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention: relationship with gene polymorphisms and clinical outcome J Am Coll Cardiol 57 2474-2483

[6] Baral S(2016)CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents Med (United States) 95 e4049-172

[7] Li JY(2013)Relationship of CYP2C19*2 and CYP2C19*3 gene polymorphism with clopidogrel response variability and recurrent cardiovascular events in Chinese patients undergoing percutaneous coronary intervention Pharmacology. 91 165-113

[8] Gao Y(2017)Genotyping, platelet activation, and cardiovascular outcome in patients after percutaneous coronary intervention: two pieces of the puzzle of clopidogrel resistance Cardiol. 137 104-508

[9] Xia YP(2012)Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel Am J Cardiol 110 502-1702

[10] He QW(2011)Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel Mol Biol Rep 38 1697-352

[1] Braun MM(2018)Stable coronary artery disease:treatment Am Fam Physician 97 376-384

[2] Stevens WABC(2015)CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: a systematic review and meta-analysis J Huazhong Univ Sci Technol - Med Sci 35 147-156

[3] Niu X(2000)Identification and biological activity of the active metabolite of clopidogrel Thromb Haemost 84 891-896

[4] Mao L(2013)Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease JACC Cardiovasc Interv 6 1166-1175

[5] Huang Y(2011)Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention: relationship with gene polymorphisms and clinical outcome J Am Coll Cardiol 57 2474-2483

[6] Baral S(2016)CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents Med (United States) 95 e4049-172

[7] Li JY(2013)Relationship of CYP2C19*2 and CYP2C19*3 gene polymorphism with clopidogrel response variability and recurrent cardiovascular events in Chinese patients undergoing percutaneous coronary intervention Pharmacology. 91 165-113

[8] Gao Y(2017)Genotyping, platelet activation, and cardiovascular outcome in patients after percutaneous coronary intervention: two pieces of the puzzle of clopidogrel resistance Cardiol. 137 104-508

[9] Xia YP(2012)Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel Am J Cardiol 110 502-1702

[10] He QW(2011)Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel Mol Biol Rep 38 1697-352